Comparative Analysis of the Binding Characteristics of Fluorescein and Rhodamine B with Bovine Serum Albumin
- 1ITMO University , , Lomonosova St. 9 , ,
- 2Sechenov First Moscow State Medical University (Sechenov University) , , ,
Abstract
Bovine serum albumin (BSA) serves as a key model for investigating protein–ligand interactions and is crucial for understanding drug pharmacokinetics and developing biomedical probes. This study presents a comprehensive comparative analysis of the binding of fluorescein and rhodamine B to BSA, employing UV–vis absorption, fluorescence, molecular docking, and 1000 ns molecular dynamics (MD) simulations. The results revealed competitive binding, with rhodamine B exhibiting a greater affinity (ΔGMMGBSA = −48.17 kcal/mol) than fluorescein (−23.16 kcal/mol), which was supported by fluorescence quenching and binding analyses. Molecular docking confirmed Sudlow’s site I as the primary binding site, whereas MD simulations highlighted stable complexes driven by van der Waals and electrostatic forces, particularly for rhodamine B. Unexpectedly, the superior affinity of rhodamine B under physiological pH deviates from lipophilic trends. These findings enhance the molecular understanding of dye–protein interactions, providing a robust basis for designing advanced fluorescent probes, drug conjugates, and diagnostic platforms.
Related
- Diene-Extended Chalcones Enable Red Fluorescence Detection of Human Serum Albumin Through FA1 Binding.
- Molecular Characterization of Lasmiditan Binding to Human Serum Albumin: Site Preference, Structural Response, and Binding Energetics
- Binding and toxicological insights into Direct Yellow 8 and bovine serum albumin: fluorescence quenching and cytotoxicity studies
- Albumin Quality in Oxidative and Ischemic Stress: Implications for Drug Binding and Clinical Pharmacokinetics
- Probing the binding dynamics of a sunitinib analog with human serum albumin: a combined spectroscopic and molecular docking approach
BibTeX
@article{afolabi2026comparative,
title = {{Comparative Analysis of the Binding Characteristics of Fluorescein and Rhodamine B with Bovine Serum Albumin}},
author = {Samson Olusegun Afolabi and Viktoria A. Feoktistova and Dmitrii Sbytov and Oleg Novikov and Anna Botnar and Sviatlana Ulasevich and Ekaterina V. Skorb and Sergey Shityakov},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.5c12646},
url = {https://pubs.acs.org/acsodf/article/11/42/64388/5450245/Comparative-Analysis-of-the-Binding},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Comparative Analysis of the Binding Characteristics of Fluorescein and Rhodamine B with Bovine Serum Albumin
AU - Samson Olusegun Afolabi
AU - Viktoria A. Feoktistova
AU - Dmitrii Sbytov
AU - Oleg Novikov
AU - Anna Botnar
AU - Sviatlana Ulasevich
AU - Ekaterina V. Skorb
AU - Sergey Shityakov
PY - 2026
DA - 2026/10/13
JO - ACS Omega
DO - 10.1021/acsomega.5c12646
UR - https://pubs.acs.org/acsodf/article/11/42/64388/5450245/Comparative-Analysis-of-the-Binding
AB - Bovine serum albumin (BSA) serves as a key model for investigating protein–ligand interactions and is crucial for understanding drug pharmacokinetics and developing biomedical probes. This study presents a comprehensive comparative analysis of the binding of fluorescein and rhodamine B to BSA, employing UV–vis absorption, fluorescence, molecular docking, and 1000 ns molecular dynamics (MD) simulations. The results revealed competitive binding, with rhodamine B exhibiting a greater affinity (ΔGMMGBSA = −48.17 kcal/mol) than fluorescein (−23.16 kcal/mol), which was supported by fluorescence quenching and binding analyses. Molecular docking confirmed Sudlow’s site I as the primary binding site, whereas MD simulations highlighted stable complexes driven by van der Waals and electrostatic forces, particularly for rhodamine B. Unexpectedly, the superior affinity of rhodamine B under physiological pH deviates from lipophilic trends. These findings enhance the molecular understanding of dye–protein interactions, providing a robust basis for designing advanced fluorescent probes, drug conjugates, and diagnostic platforms.
SN - 2470-1343
ER -